2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-141921S
    Dehydroepiandrosterone sulfate sodium-d6 1261254-41-4 99.61%
    Dehydroepiandrosterone sulfate sodium salt-d6 (DHEA sulfate sodium salt-d6; Prasterone sulfate sodium salt-d6) is the deuterium labeled Dehydroepiandrosterone sulfate sodium salt (HY-B0765). Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) sodium salt is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate sodium salt has both non-competitive antagonist activity of GABAA receptor and agonist activity of σ1 receptor. Dehydroepiandrosterone sulfate sodium salt can partially penetrate the blood-brain barrier, inhibit GABAA receptor-mediated chloride influx, enhance NMDA receptor activity through σ1 receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate sodium salt participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate sodium salt may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality.
    Dehydroepiandrosterone sulfate sodium-d6
  • HY-148410C
    Zorevunensen negative control 99.28%
    Zorevunensen (STK-001) negative control is the negative control form of Zorevunensen (HY-148410). Zorevunensen is an antisense oligonucleotide that is intended to increase the level of productive SCN1A mRNA and consequently increase the expression of the sodium channel Nav1.1 protein. Zorevunersen is used for the study of Dravet syndrome.
    Zorevunensen negative control
  • HY-P991220
    AL002 98.01%
    AL002 is a humanized monoclonal immunoglobulin G1 (IgG1) antibody and a TREM2 agonist antibody for use in neurological disease research.
    AL002
  • HY-W001542
    5-Hydroxyoxindole 3416-18-0
    5-Hydroxyoxindole is a structural analog of uric acid for its antioxidant. 5-Hydroxyoxindole has DPPH radical scavenging activities and lipid peroxidation-inhibitory activities. 5-Hydroxyoxindole is a product of partial metabolism of tryptophan involving conversion in the gut lumen of tryptophan to indole through the action of bacterial tryptophanase and tryptophan synthase. 5-Hydroxyoxindole is one of the main molecules responsible for the neurological symptoms of hepatic encephalopathy in rats. 5-Hydroxyoxindole can be used for the research of oxidative stress-mediated disorders.
    5-Hydroxyoxindole
  • HY-W012264
    3-O-Methyldopa monohydrate 200630-46-2 98.87%
    3-O-Methyldopa monohydrate (3-Methoxy-L-tyrosine monohydrate) is a significant metabolite of L-DOPA produced through the action of catechol O-methyltransferase (COMT). Unlike its precursor, 3-O-Methyldopa does not serve as a substrate or inhibitor of L-amino acid decarboxylase activity. Additionally, the inhibition of COMT can amplify the anti-Parkinson effects of L-DOPA.
    3-O-Methyldopa monohydrate
  • HY-W019815
    N-Ethyl-N-nitrosourea 759-73-9 99.92%
    N-Ethyl-N-nitrosourea (ENU) is a DNA alkylating agent. N-Ethyl-N-nitrosourea induces leukemia by alkylating nucleobases, disrupting DNA, and resulting in bone marrow suppression and the formation of leukemic cells. N-Ethyl-N-nitrosourea is teratogenic in vivo, inducing tumor formation and paw malformations in pregnant rats. N-Ethyl-N-nitrosourea cause central nervous system (CNS) tumors and genetic disorders.
    N-Ethyl-N-nitrosourea
  • HY-W081348
    1-(4-Methoxyphenyl)-3-methyl-1H-pyrazol-5(4H)-one 60798-06-3 99.54%
    1-(4-Methoxyphenyl)-3-methyl-1H-pyrazol-5(4H)-one (Compound 2) has antiprion activity in ScN2a and F3 cells with IC50 values of 13 nM and 25 nM, respectively.
    1-(4-Methoxyphenyl)-3-methyl-1H-pyrazol-5(4H)-one
  • HY-W103105
    R 29676 53786-28-0
    R 29676 is a neuroleptic agent and inhibits sodium-dependent GABA binding (GABA uptake).
    R 29676
  • HY-W419700
    L-Glutamic acid ammonium 7558-63-6 ≥98.0%
    L-Glutamic acid ammonium is an excitatory neurotransmitter.
    L-Glutamic acid ammonium
  • HY-W702712
    3-Hydroxy xylazine 145356-33-8 98%
    3-Hydroxy xylazine is a metabolite of the α2-adrenergic receptor agonist Xylazine.
    3-Hydroxy xylazine
  • HY-113123S1
    LysoPC(14:0/0:0)-d7
    LysoPC(14:0/0:0)-d7 (14:0 Lyso PC-d7) is deuterium labeled LysoPC(14:0/0:0). LysoPC(14:0/0:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. LysoPC(14:0/0:0) has potent antispasmodic effect.
    LysoPC(14:0/0:0)-d7
  • HY-B0176AS1
    (±)-cis-Sertraline-d3 hydrochloride 1217741-83-7 99.54%
    (±)-cis-Sertraline-d3 (hydrochloride) is the deuterium labeled Sertraline hydrochloride. Sertraline hydrochloride is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Sertraline hydrochloride is researched for a number of diseases, such as major depressive disorder and obsessive.
    (±)-cis-Sertraline-d3 hydrochloride
  • HY-W010155R
    Tryptophol (Standard) 526-55-6
    Tryptophol (Standard) (Indole-3-ethanol (Standard)) is an analytical standard of Tryptophol (HY-W010155). This product is intended for use in research and analytical applications.Tryptophol is an aromatic alcohol and secondary metabolite produced by microorganisms. Tryptophol induces Apoptosis and cleavage of caspase-8. Tryptophol inhibits Cunninghamella blakesleeana biofilm. Tryptophol has anti-phage infection, biofilm formation regulation, anti-inflammatory, hemolytic, sleep induction, temperature change, seizure susceptibility and immune regulation activities. Tryptophol is used in the research of African trypanosomiasis, sleep disorders, epilepsy.
    Tryptophol (Standard)
  • HY-121848
    VU0155094 731006-86-3 98.14%
    VU0155094 is a positive allosteric modulator with differential activity at the various group III mGluRs.
    VU0155094
  • HY-102024
    A2A receptor antagonist 1 443103-97-7 99.88%
    A2A receptor antagonist 1 (CPI-444 analog) is an antagonist of both adenosine A2A receptor and A1 receptor with Ki values of 4 and 264 nM, respectively.
    A2A receptor antagonist 1
  • HY-116218
    Amelparib 1227156-72-0 99.17%
    Amelparib (JPI-289 free base) is a potent, orally active, and water-soluble inhibitor of PARP-1. Amelparib inhibits PARP-1 activity (IC50=18.5 nM) and cellular PAR formation (IC50=10.7 nM) in the nanomolar range. Amelparib is a potential neuroprotective agent. Amelparib has the potential for the research of acute ischaemic stroke.
    Amelparib
  • HY-103502
    CGP7930 57717-80-3 ≥99.0%
    CGP7930 (3-(3’,5’-Di-tert-butyl-4’-hydroxy) phenyl-2, 2-dimethylpropanol) is a positive metabotropic GABAB receptor allosteric modulator. CGP7930 enhances the inhibitory effect of l-baclofen on the oscillatory activity of cultured cortical neurons.
    CGP7930
  • HY-104003
    S 38093 862896-30-8 99.86%
    S 38093 is a brain-penetrant, orally active antagonist of H3 receptor, with Kis of 8.8, 1.44 and 1.2 μM for rat, mouse and human H3 receptors, respectively.
    S 38093
  • HY-108337
    GNE-0723 1883518-31-7 98.74%
    GNE-0723 is a brain permeable positive allosteric modulator of NMDAR, with an EC50 of 21 nM for GluN2A, 7.4 and 6.2 μM for GluN2C and GluN2D, respectively.
    GNE-0723
  • HY-109131
    Foscarbidopa 1907685-81-7
    Foscarbidopa (ABBV-951; Carbidopa 4′-monophosphate) is a proagent of Carbidopa, acts as a dopamine receptor agonist.
    Foscarbidopa
Cat. No. Product Name / Synonyms Application Reactivity